Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vistagen Therapeutics Inc
(NQ:
VTGN
)
3.000
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vistagen Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder
November 30, 2022
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Publishes Positive Preclinical Findings Related to AV-101
November 17, 2022
Via
Investor Brand Network
Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease
November 17, 2022
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2023 Financial Report, Corporate Update
November 11, 2022
Via
Investor Brand Network
Exposures
Product Safety
Vistagen Reports Second Quarter Financial Results and Provides Corporate Update
November 10, 2022
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Q2 2023 Financial Results Call, Webcast
November 04, 2022
Via
Investor Brand Network
Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022
November 04, 2022
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Stifel 2022 Healthcare Conference
November 03, 2022
Via
Investor Brand Network
Vistagen to Present at Stifel 2022 Healthcare Conference
November 03, 2022
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Virtual Roundtable on Innovative Approaches to Mental Health Treatment
October 26, 2022
Via
Investor Brand Network
Vistagen to Host Concordia Live Webinar on Mental Health with Leaders from McKinsey Health Institute, WEVO, and In KidZ
October 26, 2022
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Report on 2022 Annual Meeting of Stockholders Voting, Partial Adjournment
October 20, 2022
Via
Investor Brand Network
Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022
October 19, 2022
From
Vistagen Therapeutics, Inc.
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Shares Shareholder Voting Recommendations from Leading Proxy Advisory Firms
October 06, 2022
Via
Investor Brand Network
Vistagen Announces the Two Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend Stockholders Vote “FOR” Proposal No. 5 to Provide its Board with the Option to Implement a Future Reverse Stock Split, if Necessary
October 06, 2022
From
Vistagen Therapeutics, Inc.
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) CEO to Participate at Cantor Neurology & Psychiatry Conference
October 03, 2022
Via
Investor Brand Network
Vistagen to Participate at Cantor Neurology & Psychiatry Conference
October 03, 2022
From
Vistagen
Via
Business Wire
Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit
September 20, 2022
From
Vistagen
Via
Business Wire
Vistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects
September 19, 2022
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation Schedule for Upcoming Conferences
September 09, 2022
Via
Investor Brand Network
Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences
September 09, 2022
From
Vistagen Therapeutics, Inc.
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Report FY 2023 Q1 Results, Host Conference Call and Webcast
September 08, 2022
Via
Investor Brand Network
Vistagen to Proceed with PALISADE-2 Phase 3 Clinical Trial of PH94B in Social Anxiety Disorder following Interim Analysis
September 08, 2022
From
Vistagen Therapeutics, Inc.
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2023 Financial, Corporate Report
August 12, 2022
Via
Investor Brand Network
Exposures
Product Safety
VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
August 11, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Conference Call to Discuss FY 2023 Q1 Financial Results
August 09, 2022
Via
Investor Brand Network
VistaGen Therapeutics to Report Fiscal Year 2023 First Quarter Financial Results on August 11, 2022
August 09, 2022
From
VistaGen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for PH94B
July 22, 2022
Via
Investor Brand Network
VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B
July 22, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at 2022 Concordia Americas Summit; CEO and US Surgeon General to Discuss Mental Health Crisis
July 12, 2022
Via
Investor Brand Network
Exposures
COVID-19
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.